Can Risk Scores for Vascular Disease in Gout Patients be Improved?

  • Lynda G. Darlington
  • James T. Scott
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 253A)


Since reductions have occurred in mortality from ischaemic heart disease in the USA (1) and in the United Kingdom (2) concurrently with reductions in consumption of tobacco and dairy produce, increased intake of polyunsaturated fats and awareness of the benefits of regular exercise, it seems reasonable to attribute the declining mortality at least in part to the effects of these changes in lifestyle.


Coronary Heart Disease Risk Score Ischaemic Heart Disease Coronary Risk Coronary Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. J. Walker, 1977, New England Journal of Medicine, 297: 163–5.PubMedCrossRefGoogle Scholar
  2. 2.
    C. du V. Florey, R. J. W. Melia and S. C. Darby, 1978, Changing mortalit from ischaemic heart disease in Great Britain 1968-76. Br. Med. J., 1: 635–7.CrossRefGoogle Scholar
  3. 3.
    F. Fidanza, 1972, Epidemiological evidence for the fat theory. Proc. Nutr. Soc., 31: 317–21.PubMedCrossRefGoogle Scholar
  4. 4.
    B. Lewis, J. I. Mann and M. Mancini, 1986, Reducing the risks of coronary heart disease in individuals and in the population. Lancet, i: 956CrossRefGoogle Scholar
  5. 5.
    P. Puska, J. Tuomilehto, J. Salonen, L. Neittaanmäki, J. Maki, J. Virtamo, A. Nissinen, K. Koskela and T. Takalo, 1979, Changes in coronary risk factors during comprehensive five year community programme to control cardiovascular disease (North Karelia project). Br. Med. J., 2: 1173–78.PubMedCrossRefGoogle Scholar
  6. 6.
    L. L. Basta, C. Williams, J. M. Kioschos and A. A. Spector, 1976, Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidaemia. Am. J. Med., 81: 420–3.CrossRefGoogle Scholar
  7. 7.
    R. Barndt, D. H. Blankenhorn, D. W. Crawford and S. H. Brooks, 1977, Regression and Progression of Early Femoral Atherosclerosis in Treated Hyperlipoproteinaemic Patients. Ann. Intern. Med., 86: 139–146.PubMedGoogle Scholar
  8. 8.
    L. G. Darlington, J. Slack and J. T. Scott, 1983, Vascular mortality in patients with gout and in their families. Ann. Rheum. Dis, 42: 270–73.PubMedCrossRefGoogle Scholar
  9. 9.
    A. P. Hall, 1965, Correlations among hyperuricaemia, hypercholesterol-aemia, coronary disease and hypertension. Arthr. Rheum., 8: 846–52CrossRefGoogle Scholar
  10. 10.
    B. T. Nobbs, J. M. Smith and A. W. Walker, 1977, Enzymic determination of plasma cholesterol on discrete automatic analysers. Clinical Chimica Acta, 79: 391–7.CrossRefGoogle Scholar
  11. 11.
    P. Fossati and L. Prencipe, 1982, Serum triglycerides determined colori metrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 28: 2077–80.PubMedGoogle Scholar
  12. 12.
    M. Eggstein and F. H. Kreutz, 1966, Eine neue Bestimmung der Neutralfette I. Klin. Wschr., 44: 262–267.PubMedCrossRefGoogle Scholar
  13. 13.
    W. B. Kannel, T. R. Dawber, G. D. Friedman, W. E. Glennon and P. M. McNamara, 1964, Risk Factors in Coronary Heart Disease. An Evaluation of Several Serum Lipids as Predictors of Coronary Heart Disease. The Framing-ham Study. Ann. Intern. Med., 61: 888–899.PubMedGoogle Scholar
  14. 14.
    P. Williams, D. Robinson and A. Bailey, 1979, High-Density Lipoprotein and Coronary Risk Factors in Normal Men. Lancet, i: 72–75.CrossRefGoogle Scholar
  15. 15.
    J. Slack, N. Noble, T. W. Meade, W. R. S. North, 1977, Lipid and lipoprotein concentrations in 1604 men and women in working populations in north-west London. Br. Med. J., 2: 353–56PubMedCrossRefGoogle Scholar
  16. 16.
    S. J. Pocock, A. G. Shaper, A. N. Phillips, M. Walker, T. P. Whitehead, 1986, High density lipoprotein cholesterol is not a major risk factor for ishcaemic heart disease in British men. Br. Med. J., 292: 515–19.CrossRefGoogle Scholar
  17. 17.
    J. L. Beaumont, L. A. Carlson, G. R. Cooper, Z. Fejfar, D. S. Fredrick-son, T. Strasser, 1970, Classification of hyperlipidaemias and hyperlipopro-teinaemias. Bulletin of the World Health Organisation, 43: 891–915.Google Scholar
  18. 18.
    L. R. Krasno and G. J. Kidera, 1972, Clofibrate in Coronary Heart Disease. J.A.M.A., 219: 845–51PubMedCrossRefGoogle Scholar
  19. 19.
    L. A. Carlson, M. Danielson, I. Ekberg, B. Klintemar and G. Rosenhamer, 1977, Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis, 28: 81–6.PubMedCrossRefGoogle Scholar
  20. 20.
    J. McMichael, 1979, Fats and atheroma: an inquest. Br. Med. J., 1: 173–175.PubMedCrossRefGoogle Scholar
  21. 21.
    H. Geizerova, I. Gyarfas, K. G. Green, J. A. Heady et al, 1980, WHO Co-operative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow up. Lancet, ii: 379–85.Google Scholar
  22. 22.
    Lipid Research Clinics Coronary Primary Prevention Trials Results, 1984. J.A.M.A., 251: 351-64.Google Scholar
  23. 23.
    M. H. Frick, O. Elo, K. Haapa, O. P. Heinonen et al, 1987, Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil In Middle-Aged Men With Dyslipidaemia: Safety of Treatment, Changes in Risk Factors and Incidence of Coronary Heart Disease. N. Engl. J. Med., 317: 1237–45.PubMedCrossRefGoogle Scholar
  24. 24.
    M. F. Oliver, H. Geizerova, I. Gyarfas, K. G. Green et al, 1978, A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40: 1069–1118.CrossRefGoogle Scholar
  25. 25.
    I. C. Ononogbu, 1977, High density lipoprotein in ischaemic heart disease. Experientia, 33: 1063–64.PubMedCrossRefGoogle Scholar
  26. 26.
    T. Gordon, W. P. Castelli, M. C. Hjortland, W. B. Kannel, T. R. Dawber, 1977, High Density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62: 707–714.Google Scholar
  27. 27.
    D. R. Jacobs Jr. (for the Lipid Research Clinics Follow Up Study), High density lipoprotein-cholesterol (HDL-C) and coronary heart disease (CHD), cardiovascular disease (CVD) and all cause mortality. Circulation, 72: 111–185.Google Scholar
  28. 28.
    S. Yaari, U. Gouldbourt, S. Even-Zohar, H. N. Neufeld, 1981, Association of Serum High Density Lipoprotein And Total Cholesterol With Total, Cardiovascular And Cancer Mortality In A 7-year Prospective Study of 10, 000 Men. Lancet, i: 1011–15.CrossRefGoogle Scholar
  29. 29.
    U. Goldbourt, E. Holtzman, H. N. Neufeld, 1985, Total and high density lipoprotein cholesterol in the serum and risk of mortality evidence of a threshold effect. Br. Med. J., 290: 1239–43.CrossRefGoogle Scholar
  30. 30.
    W. P. Castelli, J. T. Doyle, T. Gordon, C. G. Hames et al, 1977, Lancet ii: 153–5.CrossRefGoogle Scholar
  31. 31.
    L. G. Darlington and J. T. Scott, 1972, Plasma lipidlevels in gout. Ann. Rheum. Dis, 31: 487–489.PubMedCrossRefGoogle Scholar
  32. 32.
    H. Mielants, E. M. Veys, A. de Weerdt, 1973, Gout and its relation to lipid metabolism I serum uric acid, lipid and lipoprotein levels in gout. Ann. Rheum. Dis., 32: 501–505.PubMedCrossRefGoogle Scholar
  33. 33.
    T. Gibson and R. Grahame, 1974, Gout and hyperlipidaemia. Ann. Rheum. Dis., 33: 298–303.PubMedCrossRefGoogle Scholar
  34. 34.
    L. G. Parlington, 1984, Lean dry gout patients in “Purine Metabolism in Man — IV. Clinical and Therapeutic Aspects; Regulatory Mechanisms”, C. H. M. M. de Bruyn, H. A. Simmonds and M. M. Muller eds., Plenum Press, New York.Google Scholar
  35. 35.
    S. Jiao, K. Kameda, Y. Matsuzawa and S. Tourui, 1986, Hyperlipoprotein-aemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan. Ann. Rheum. Dis, 45: 308–313.PubMedCrossRefGoogle Scholar
  36. 36.
    L. A. Carlson, L. E. Bottiger, 1972, Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Lancet, i: 865–8.CrossRefGoogle Scholar
  37. 37.
    R. G. Wilcox, 1978, Serum lipid concentrations and blood pressure in obese women. Br. Med. J., i: 1513–1515.CrossRefGoogle Scholar
  38. 38.
    D. A. Streja, E. Boyka and S. W. Rabkin, 1980, Changes in plasma high-density lipoprotein cholesterol concentration after weight reduction in grossly obese subjects. Br. Med. J., 281: 770–772.PubMedCrossRefGoogle Scholar
  39. 39.
    W. B. Kannel, M. C. Hjortland, P. M. McNamara, T. Gordon, 1976, Menopause and risk of cardiovascular disease. The Framingham Study. Ann. Intern. Med., 85: 447–452.PubMedGoogle Scholar
  40. 40.
    M. F. Oliver, G. S. Boyd, 1959. Lancet, ii: 690–694.CrossRefGoogle Scholar
  41. 41.
    The Coronary Drug Project. J.A.M.A., 214: 1303-1313.Google Scholar
  42. 42.
    Lancet Editorial, 1978, Oestrogens and atheroma. Lancet, ii: 508-10.Google Scholar
  43. 43.
    N. Hickey, R. Mulcahy, G. J. Bourke, I. Graham and K. Wilson-Davis, 1975, Study of coronary risk factors related to physical activity in 15171 men Br. Med. J., 3: 507–9.PubMedCrossRefGoogle Scholar
  44. 44.
    J. N. Morris, J. W. Marr and D. G. Clayton, 1977, Diet and heart: a postscript. Br. Med. J., 2: 1307–14.PubMedCrossRefGoogle Scholar
  45. 45.
    A. Lehtonen and J. Viikari, 1978, The Effect of vigorous physical activity at work on serum lipids with a special reference to serum high-density lipoprotein cholesterol. Acta. Physiol. Scan., 104: 117–121.CrossRefGoogle Scholar
  46. 46.
    S. Punsar, M. J. Karvonen, Physical activity and coronary heart disease in populations from East and West Finland. Advances in Cardiology, 18: 196–207.Google Scholar
  47. 47.
    K. Ball and R. Turner, 1974, Smoking and the heart. The basis for action. Lancet, ii: 822–826.CrossRefGoogle Scholar
  48. 48.
    W. B. Kannel and T. R. Dawber, 1974, Hypertension as an ingredient of cardiovascular risk profile. Br. J. Hosp. Med., 11: 508–23.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Lynda G. Darlington
    • 1
  • James T. Scott
    • 2
  1. 1.Epsom District HospitalRheumatology UnitEpsom, SurreyUK
  2. 2.Kennedy Institute of RheumatologyLondon W6UK

Personalised recommendations